It was found that the NSCLC patients with IMP3 expression exhibited lower disease-free (log-rank=17.719, P<0.001) and overall (log-rank=19.281, P<0.001) survival rates compared with those patients without IMP3 expression (Fig. 3). Here, IMP3 is linked to non-small cell lung carcinoma.